On December 8, 2021, Clinigen Group has agreed to be snapped up by UK-based private equity firm Triton Investment Management in a deal that values the pharmaceutical services company at around £1.2billion. Triton has offered 883p a share in cash, with shareholders also eligible to receive a previously declared final dividend of 5.46p per the Company share. Clinigen confirmed it was in advanced talks with Triton over a possible deal, amid reports of activist investor Elliott Management raising its stake to propose a break up of Clinigen.